Advisory Panel of Experts Endorses F.D.A. Approval of New Alzheimer’s Drug

Off Health News

The modest benefits of the treatment, donanemab, made by Eli Lilly, outweigh the risks, the panel concluded unanimously.

View original article
Contributor: Gina Kolata and Pam Belluck

About The Author